Overview

EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients

Status:
Completed
Trial end date:
2018-05-16
Target enrollment:
Participant gender:
Summary
This study is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of CTX-4430 administered once-daily for 48 weeks for treatment of CF.
Phase:
Phase 2
Details
Lead Sponsor:
Celtaxsys, Inc.